Cite
HARVARD Citation
Blauvelt, A. et al. (2019). Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate‐to‐severe psoriasis: a pooled analysis of two randomized controlled trials. Journal of the European Academy of Dermatology and Venereology. pp. 2305-2312. [Online].